GlobeNewsWire · IMCR · October 29, 2026

Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting

Get the app for more

Explore stock news, insights and company research.